Background: Pompe disease is a rare metabolic disorder caused by a deficiency of the lysosomal enzyme acid α-glucosidase. Glycogen accumulation damages skeletal, cardiac, and smooth muscles, causing a progressive and debilitating muscle weakness and cardiomyopathy. As life expectancy has much improved since the introduction of enzyme replacement therapy an increasing number of patients are referred for surgical procedures. Due to the potential cardiopulmonary complications, these patients form a high-risk group for the anesthesiologist. Aims: In this study, we investigated the incidence of perioperative complications in children with Pompe disease treated in our hospital since the introduction of enzyme replacement therapy. Methods: Anesthe...
Introduction: Glycogen Storage disease type 2 (GSD II), also known as Pompe disease is caused by a d...
Contains fulltext : 52492.pdf (publisher's version ) (Closed access)BACKGROUND: Ch...
Pompe disease also known as glycogen storage disease type II, is a rare and progressive lysosomal st...
Pompe disease (PD) is a rare, inherited autosomal recessive metabolic disorder caused by the deficie...
Ilka Schneider, Stephan Zierz Department of Neurology, Martin Luther University Halle-Wittenberg, Ha...
Objective. Infantile Pompe's disease is a lethal cardiac and muscular disorder. Current developments...
Objective. Infantile Pompe's disease is a lethal cardiac and muscular disorder. Current developments...
OBJECTIVE: Infantile Pompe's disease is a lethal cardiac and muscular disorder. Current developments...
Pompe disease is a metabolic myopathy. Since the first description of the disease in 1932 by J.C. P...
Pompe disease is a rare metabolic myopathy caused by deficiency of lysosomal α-glucosidase. Reduced ...
The glycogen storage disease type II (GSD-II), or Pompe disease, is due to the deficit of lysosomal ...
Pompe disease (PD) is an autosomal recessive disease caused by partial or complete deficiency of the...
Pompe disease (PD) is an autosomal-recessively inherited neuromuscular disease that, if not diagnose...
Juan Francisco Cabello,1 Deborah Marsden21Genetics and Metabolic Disease Laboratory, Nutrition and F...
J Inherit Metab Dis. 2010 Sep 10. [Epub ahead of print] Long-term follow-up results in enzyme replac...
Introduction: Glycogen Storage disease type 2 (GSD II), also known as Pompe disease is caused by a d...
Contains fulltext : 52492.pdf (publisher's version ) (Closed access)BACKGROUND: Ch...
Pompe disease also known as glycogen storage disease type II, is a rare and progressive lysosomal st...
Pompe disease (PD) is a rare, inherited autosomal recessive metabolic disorder caused by the deficie...
Ilka Schneider, Stephan Zierz Department of Neurology, Martin Luther University Halle-Wittenberg, Ha...
Objective. Infantile Pompe's disease is a lethal cardiac and muscular disorder. Current developments...
Objective. Infantile Pompe's disease is a lethal cardiac and muscular disorder. Current developments...
OBJECTIVE: Infantile Pompe's disease is a lethal cardiac and muscular disorder. Current developments...
Pompe disease is a metabolic myopathy. Since the first description of the disease in 1932 by J.C. P...
Pompe disease is a rare metabolic myopathy caused by deficiency of lysosomal α-glucosidase. Reduced ...
The glycogen storage disease type II (GSD-II), or Pompe disease, is due to the deficit of lysosomal ...
Pompe disease (PD) is an autosomal recessive disease caused by partial or complete deficiency of the...
Pompe disease (PD) is an autosomal-recessively inherited neuromuscular disease that, if not diagnose...
Juan Francisco Cabello,1 Deborah Marsden21Genetics and Metabolic Disease Laboratory, Nutrition and F...
J Inherit Metab Dis. 2010 Sep 10. [Epub ahead of print] Long-term follow-up results in enzyme replac...
Introduction: Glycogen Storage disease type 2 (GSD II), also known as Pompe disease is caused by a d...
Contains fulltext : 52492.pdf (publisher's version ) (Closed access)BACKGROUND: Ch...
Pompe disease also known as glycogen storage disease type II, is a rare and progressive lysosomal st...